Clinical trial
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00082966 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00082966 |
|---|---|
| Title | Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma |
| Official title | A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | 17-N-allylamino-17-demethoxygeldanamycin/bortezomib |
| Enrollment | 43 |
| Start date | Mar 1, 2004 |
| Primary completion | Mar 1, 2007 |
| First posted | May 17, 2004 |
| Last update posted | Dec 4, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: